Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Patent
1997-04-11
2000-01-04
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
424468, 424480, A61K 920, A61K 922, A61K 936
Patent
active
060107189
ABSTRACT:
Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower C.sub.max in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
REFERENCES:
patent: 3870790 (1975-03-01), Lowey et al.
patent: 4226849 (1980-10-01), Schor
patent: 4369172 (1983-01-01), Schor et al.
patent: 4808411 (1989-02-01), Lu et al.
patent: 4842866 (1989-06-01), Horder et al.
patent: 5393765 (1995-02-01), Infeld et al.
Die Pharmazie, vol. 50, No. 4 (Feb. 1995), pp. 154-155, J. Rak et al., "Matrixtabletten aus Niedrigviskoser Hydropromellose".
Journal of Controlled Release, vol. 12 (1990), pp. 133-141, K.V. Ranga Rao et al., "Influence of Molecular Size and Water Solubility of the Solute on Its Release from Swelling and Erosion Controlled Polymeric Matrices".
Al-Razzak Laman
Crampton Sheri L.
Gustavson Linda E.
Hui Ho-Wah
Milman Nelly
Abbott Laboratories
Anand Mona
Howard Sharon
Page Thurman K.
LandOfFree
Extended release formulations of erythromycin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Extended release formulations of erythromycin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Extended release formulations of erythromycin derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1070561